Stocks and Investing
Stocks and Investing
Thu, February 2, 2023
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Wed, February 1, 2023
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Rick Bienkowski Initiated (VERV) at Hold and Held Target at $21 on, Feb 1st, 2023
Rick Bienkowski of Cantor Fitzgerald, Initiated "Verve Therapeutics, Inc." (VERV) at Hold and Held Target at $21 on, Feb 1st, 2023.
Rick has made no other calls on VERV in the last 4 months.
There are 3 other peers that have a rating on VERV. Out of the 3 peers that are also analyzing VERV, 1 agrees with Rick's Rating of Hold. Following is the relevant analyst calls for the last 4 months
- Richard Law of "Credit Suisse" Initiated at Hold and Held Target at $48 on, Thursday, October 6th, 2022
These are the ratings of the 2 analyists that currently disagree with Rick
- Andrea Tan of "Goldman Sachs" Initiated at Strong Sell and Held Target at $13 on, Thursday, December 15th, 2022
- Luca Issi of "RBC Capital" Maintained at Buy with Decreased Target to $35 on, Tuesday, November 8th, 2022
Contributing Sources